SCYNEXIS Announces Pricing of $45 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants

3 years ago

JERSEY CITY, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) today announced the pricing of its underwritten…

Opthea strengthens its Board of Directors

3 years ago

Elects Mr. Quinton Oswald and Dr. Susan Orr, deeply experienced Ophthalmology Executives, at a General Meeting of ShareholdersMELBOURNE, Australia, April 22, 2022 (GLOBE NEWSWIRE) --…

BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics

3 years ago

SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to…

Entourage Updates Timing of Fiscal Year 2021 Financial Results Call to May 3, 2022

3 years ago

Company reaffirms preliminary fiscal year 2021 record revenue of $54.8 million(1)Results to be filed after-market May 2, 2022, with management…

Vallon Pharmaceuticals Announces Review of Strategic Alternatives

3 years ago

Philadelphia, PA, April 22, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical…

Ultragenyx Appoints Amrit Ray, M.D., M.B.A. to Board of Directors

3 years ago

Physician researcher and biopharmaceutical executive to join R&D Committee Amrit Ray, M.D., M.B.A. Amrit Ray, M.D., M.B.A.NOVATO, Calif., April 22,…

SCYNEXIS Announces Positive Interim Data from Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp’s Potency Against Severe Fungal Infections

3 years ago

Data reinforce findings from previous analyses demonstrating oral ibrexafungerp’s potential to combat difficult-to-treat and refractory fungal infections in the hospital…

Jasper Therapeutics to Host In-Person Key Opinion Leader Webinar on Transforming Hematopoietic Stem Cell Therapies

3 years ago

REDWOOD CITY, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic…

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results

3 years ago

SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical…

Simply Better Brands Corp. Announces Shares for Debt Transaction

3 years ago

VANCOUVER, British Columbia, April 22, 2022 (GLOBE NEWSWIRE) -- Simply Better Brands Corp. ("SBBC" or the "Company") (TSX Venture: SBBC,…